ACRS•benzinga•
Aclaris Therapeutics Has Initiated A Randomized, Double-blind, Placebo-Controlled Phase 2 Trial Of Bosakitug (ATI-045) For Moderate-to-severe Atopic Dermatitis, Top Line Results Expected In The Second Half Of 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga